BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211206
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210817T215306Z
LAST-MODIFIED:20210817T215306Z
UID:31360-1638748800-1639094399@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy for Neurological Disorders
DESCRIPTION:Returning to Boston this December\, the 3rd Gene Therapy for Neurological Disorders meeting will welcome discovery\, preclinical\, translational and clinical industry scientists to share\, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS. \nWith 40+ expert leaders from the likes of Taysha Gene Therapies\, Passage Bio\, AskBio\, Neurogene\, Affinia Therapeutics and Alcyone Therapeutics sharing their progress\, don’t miss the chance to join the industry’s definitive physical conference to make new connections and reconnect with your friends and colleagues. \nOver 4 comprehensive days of networking\, presentations and discussion sessions\, this meeting will enable you to: \n\nDiscuss the latest DRG toxicity and immunogenicity research to understand the biology behind AAV toxicity in the CNS\nEvaluate current safety and toxicity strategies to navigate off target effects including redosing options\nEvaluate intraparenchymal\, intra-cisterna magna\, lumbar intrathecal and systemic delivery routes for CNS indications to assess CNS tropism and biodistribution\nHear from neurosurgeons at the forefront of delivery and explore the most up to date delivery devices to identify novel innovations and areas for development\nReview pharmacological concepts for preclinical dose selection in NHP biodistribution case studies to optimize dose extrapolation\nLearn about the different vector discovery strategies used to identify vectors with improved CNS tropism and specificity\nOptimize clinical trial design considerations for both paediatric and adult neurological patient populations to showcase efficacy to regulators and deliver value for patients\nDiscover the novel indications being targeted by gene therapies such as epilepsy\, neuropathic pain and hearing disorders to improve your knowledge of current CNS pipelines\n\nView your copy of the event guide now: https://ter.li/yrofx9
URL:https://www.pharmajournalist.com/event/3rd-gene-therapy-for-neurological-disorders/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210812T114045Z
LAST-MODIFIED:20210812T114045Z
UID:31282-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:iPSC-Derived Cell Therapies Summit
DESCRIPTION:Capitalize on the Scalable & Diverse Potential of iPSC-Derived Therapies By Defining Differentiation Protocols\, Optimal Cell Line Selection & Optimizing Gene Engineering To Accelerate Successfully Into the Clinic \nThe explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy\, with these cells establishing its place as the optimal starting material for cell therapies targeting cancer\, autoimmune\, cardiac disease and much more. \nThe iPSC-Derived Cell Therapies Summit is your dedicated forum exclusively focused on the common challenges across disease indications which are limiting the clinical translation of iPSC-based approaches for cell therapy\, including safety concerns with differentiation protocols\, lack of regulatory guidance\, and licensing issues. \nGet caught up to speed on this dynamic industry with expertise shared from the likes of Shoreline Biosciences\, Kite Pharma\, HeartSeed\, and Exacis\, to understand the broad applicability of iPSCs\, advances in novel gene engineering approaches\, and translational lessons learned to advance your pipeline to clinical success. \nLeave this meeting with the knowledge and connections to landscape the clinical progression\, outline GMP compliant processes for scale up\, and share strategies to ensure consistency in starting material. \nThis is your opportunity to collaborate with 80+ iPSC senior level experts from biopharma and academia and be at the forefront of the future of cell therapy by joining the mission to develop safe\, scalable and cost-effective iPSC-derived therapies. \nTo Know more visit: https://ter.li/e7gdu7
URL:https://www.pharmajournalist.com/event/ipsc-derived-cell-therapies-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210819T081104Z
LAST-MODIFIED:20210819T081104Z
UID:31364-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:Synthetic Biology-Based Therapeutics Summit
DESCRIPTION:Engineer ‘Intelligent’\, Controllable Drugs at the First Technical Meeting Dedicated to Advancing the Therapeutic Applications of Synthetic Biology \nThis year\, the synthetic biology market has seen fledgling companies rise to IPO smashing power players\, as the demand for high-quality\, engineered biomolecules and controllable therapeutics grows exponentially. \nThe therapeutic potential of novel synthetic units is huge\, but challenges remain in demonstrating proof-of-concept\, developing assays\, functional characterization\, manufacturing scale-up\, and identifying therapeutic applications for commercial development. \nWith an agenda curated by leaders in synthetic biology-based therapies at Synlogic\, Merck\, Bayer\, Senti Bio\, MIT and GSK\, the Synthetic Biology-Based Therapeutics Summit will provide strategic insights to deploy synthetic biology as a tool for discovery\, through to therapeutic applications. \nExplore innovations in circuit design and implementation\, harnessing the power of computation and AI to better design functioning circuits and uncover novel components which elicit therapeutic benefit. Tackle manufacturing challenges to scale up synthetic biology-based therapeutics with gold-standard quality control and characterization. \nTo Know more visit: https://ter.li/19 mj8t
URL:https://www.pharmajournalist.com/event/synthetic-biology-based-therapeutics-summit/
LOCATION:Digital | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210823T104601Z
LAST-MODIFIED:20210823T104827Z
UID:31394-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:3rd Annual Targeted Radiopharmaceuticals (TRP) Summit 
DESCRIPTION:The 3rd Targeted Radiopharmaceuticals (TRP) Summit returns at a crucial time for the entire industry. Spurred on by positive Phase III VISION trial data\, there has been huge research investment\, on both sides of the Atlantic\, on how to deliver radiation therapy directly and specifically to tumours. \nFor the 2021 edition of this conference\, there will be the opportunity to attend either in-person in Berlin or remotely via a dedicated digital networking platform with all the access to the conference content. \nYou can expect a wider array of insights from recent case studies to help you accelerate the development of the next generation of radioligand therapies from clinical approval to commercialisation. \nAs the only industry-led platform for discussing challenges and opportunities facing developers of theranostic radioligand therapies\, we strive to tackle topics that are on every drug developer’s mind: \n\nHow do we identify and validate new targets?\nCan we combine Targeted Radiopharmaceuticals with immunotherapy or other targeted oncology methods?\nHow do we improve current clinical design methodologies and patient selection strategies?\nWhere can improvements be made to the current supply and fulfilment models?\n\nTo know more visit: https://ter.li/r1oll2
URL:https://www.pharmajournalist.com/event/3rd-annual-targeted-radiopharmaceuticals/
LOCATION:Berlin Germany\, & Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210826T090709Z
LAST-MODIFIED:20210826T090829Z
UID:31471-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:4th Commercializing Clinically Validated Digital Therapeutics Summit
DESCRIPTION:The 4th Commercializing Clinically Validated Digital Therapeutics Summit returns in December of 2021 as the only industry-led meeting deep-diving on stakeholder alliance and partnership to accelerate DTx scalability\, to enable building sustainable & viable business models. \nDTx is happening\, and happening fast on a global scale. The amount of investment continues to surge\, and is expected to reach $15\,176m in 2027. Following the pandemic\, with more emphasis on digital medicine\, telemedicine\, and decentralized clinical trials\, DTx adoption has peaked. Now is the time to join with key stakeholders across regulatory\, pricing\, physician engagement\, real world evidence\, commercial functions\, patient adherence and adoption to combat the challenges and ensure delivery of cutting edge DTx to your patients. \n \nFurthermore\, the pandemic has been the major catalyst to DTx adoption with tremendous benefits brought to patients\, physicians for treatment\, and remote clinical trials that made 2021 an inflection point for the DTx industry. \nAcross 3 days covering extensive and valuable content\, we will bring together expert speakers to share their data on case studies of lessons learnt and keys to success\, as well as insights into venturing into effective partnerships. This will give you the tools to conquer your most crucial challenges and accelerate sustainable scalability and adoption of your digital therapeutic. \nWhether you are a drug\, med device or a DTx developer\, this is your must-attend event in 2021. Hear from your peers’ journeys and lessons learned\, and re-engage in the long awaited dialogue to generate clinical and RWE\, in order to serve our patients in need beyond just a pill! \nTo know more visit: https://ter.li/cyw0ze
URL:https://www.pharmajournalist.com/event/4th-commercializing-clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210903T051629Z
LAST-MODIFIED:20210903T133327Z
UID:31553-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:4th RNA-Targeted Drug Discovery Summit
DESCRIPTION:The 4th RNA-Targeted Drug Discovery Summit is returning once again this December\, to reunite the largest community of thought leaders and experts in biology\, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity\, selectivity and drug-like properties. \nJoin the leading RNA small molecule forum alongside 150+ biopharmaceutical Directors\, VPs and C-Level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field. \nWe’re back in 2021 with a more comprehensive program than ever before & we’d love you to join us! \nKey Highlights: \n\nExpand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum\, Arrakis\, PTC Bio& Expansion Therapeutics\n\n\nOptimize and advance your RNA structural insights to guide the successful discovery & development of your RNA targeted small molecule with insights from Novartis\, AstraZeneca\, Stanford University &National Cancer Institute\n\n\nEvaluate tested & novel structure-based methods for understanding RNA-ligand interactions and binding sites alongside academic leaders Hashim Al-Hashimi\, Matthew Disney\,Amanda Garner\, Aaron Frank & Anthony Mustoe\n\n\nOvercome selectivity\, specificity & toxicity challenges and accelerate the translation of your RNA small molecule pipeline into clinical development with discussions from\nAnima Biotech\, MD Anderson Cancer Center & AstraZeneca\n\n\nDiscovery of novel chemical matter & new chemical space for small molecule intervention with insights from Roche\, University of Michigan\, Baylor College Medicine\, Remix Therapeutics\, Ladder Therapeutics &Biosplice Therapeutics\n\nTo know more visit: https://bit.ly/3mWyANC
URL:https://www.pharmajournalist.com/event/4th-rna-targeted-drug-discovery-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211209
DTSTAMP:20260515T223536
CREATED:20210913T100540Z
LAST-MODIFIED:20210913T100540Z
UID:31669-1638835200-1639007999@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Gut Therapeutics Europe
DESCRIPTION:Join us in Amsterdam from 7th – 8th December 2021 to find out more about why biotherapeutic products are progressing through clinics worldwide. As this trending topic gains more exposure and fast approaches commercialisation various challenges have presented themselves. Issues in areas such as key regulatory\, manufacturing and supply chain are amongst some of the themes emerging. \nCompanies such as Stellate Therapeutics\, TargEDys\, EVERIMMUNE\, Nestlé are amongst those committed to the event\, and you can reach out to them directly by securing your place. \nDownload the agenda here to view the speaker faculty and partners for 2021: https://hubs.ly/H0X0Lk_0
URL:https://www.pharmajournalist.com/event/microbiome-connect-gut-therapeutics-europe/
LOCATION:Amsterdam\, Venue TBC
ORGANIZER;CN="Hanson Wade":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211207
DTEND;VALUE=DATE:20211210
DTSTAMP:20260515T223536
CREATED:20210917T065655Z
LAST-MODIFIED:20210917T065655Z
UID:31690-1638835200-1639094399@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Summit
DESCRIPTION:TIGIT therapies have seen promising clinical validation\, spearheading the next wave of Immune Checkpoint Inhibitors. As such there has been an explosion of interest and high-scale investment into this exciting space. \nArriving at a critical point for TIGIT development\, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused at propelling this next generation inhibitor to clinical use. \nEnsure your TIGIT program reaches full clinical potential through hearing from experts about optimizing the mechanism of action\, refining Fc receptor co-engagement\, devising effective drug design\, rationalizing checkpoint combinations and utilizing biomarkers to harness the therapeutic potential of the TIGIT and DNAM-1/CD226 axes. \nJoin leaders in TIGIT development from GSK\, Gilead Sciences\, Arcus\, iTeos\, Compugen\, BeiGene\, Seattle Genetics\, Mereo BioPharma\, Harvard\, Stanford and more! \nThis event will allow you to address the key challenges associated with TIGIT therapy development and propel TIGIT to clinical use. Download the event guide to see how you can get involved.
URL:https://www.pharmajournalist.com/event/tigit-therapies-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211210
DTEND;VALUE=DATE:20211212
DTSTAMP:20260515T223536
CREATED:20211202T113910Z
LAST-MODIFIED:20211202T113910Z
UID:32314-1639094400-1639267199@www.pharmajournalist.com
SUMMARY:INDIAN PHARMA EXPO & BUSINESS EXCELLENCE AWARDS 2021
DESCRIPTION:Indian Pharma Expo (IPE) will provide an opportunity for the participating companies to display their products & services to the gamut of visitors\, globally from pharma and healthcare industries. The 2-day expo will bring together eminent personalities from various sectors of pharma\, non-pharma and healthcare industries. IPE is one stop juncture to all those who are planning to expand their business through various channels of franchise and distribution; as well as wholesalers and hospital purchase personnels who seek to buy bulk products on concessional rates. \n The Indian Pharma Expo will also showcase the latest trend and technologies in the pharmaceuticals\, drugs and formulations. The Expo is expected to witness approx. 10\,000 visitor’s footfall displays of latest pharmaceutical machinery\, packaging equipments\, software technology for pharma industry and management and more. Direct access to highly targeted senior pharma executives\, buyers\, procurement managers\, contract manufacturers and hospital administration. Multiple meetings will be held with managers and business development managers who are looking for new supplies\, building strategic partnerships or entering into new ventures. The Expo will feature international-cum-pharma machinery pavilion. The Expo aimed at bringing together all the pharma professionals under one roof\, the pharmaceutical exhibition focused on knowledge\, technology and business development.
URL:https://www.pharmajournalist.com/event/indian-pharma-expo-business-excellence-awards-2021/
LOCATION:Hall 12 A\, Pragati Maidan\, New Delhi\, New Delhi\, 110001\, India
ORGANIZER;CN="CIMS Medica":MAILTO:anisha.n@cims.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220112
DTEND;VALUE=DATE:20220114
DTSTAMP:20260515T223536
CREATED:20211021T082933Z
LAST-MODIFIED:20211214T010209Z
UID:31857-1641945600-1642118399@www.pharmajournalist.com
SUMMARY:SMi's Pre-Filled Syringes and Injectable Drug Devices
DESCRIPTION:SMi’s Pre-Filled Syringes and Injectable Drug Devices \n12th January to 13th January 2022\,\nVirtual Conference: Online Access Only\nConference: 12 – 13 January 2022\nFocus Day: 11 January 2022\nLocation: Virtual Conference: Online Access Only\nWebsite: http://pre-filled-syringes.com/pharmajournalist/WL \nSponsored by: BD Medical – Pharmaceutical Systems\, Crux\, Nemera\, Zeon Europe GmbH \nChaired by: \nBjørg Kaae Hunter\, Department Manager\, RA CMC & Device; RA NextGen Drug-Device\, Novo Nordisk and Daniel Latham\, Head Connected Health Product Development\, Novartis \nThe Future of Drug Delivery and Combination Product Device Design \nThe pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics\, high concentration\, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is adapting to the delayed EU MDR\, takeaways from the global pandemic and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. Part of the leading injectables series of events\, SMi’s 14th annual conference will bring you the key insights you need to grow and enhance your pre-filled syringes portfolio and discover what the future holds for the PFS and combination products industry. \n#PFSSMi \nKey Reasons to Attend: \n\nEngage with industry leaders on the key takeaways from the pandemic and how this can be applied to future accelerated development\nExplore updates to drug device combination product design approaches putting the user first with industry case studies from big pharma\nAssess the current landscape of device delivery mechanisms and how industry can work together to promote innovation\nUnderstand the landscape of delivery for novel drug products\, fragile molecules and long acting injectables in the interactive panel discussion\n\nDownload the brochure at: http://pre-filled-syringes.com/pharmajournalist/WL \nWho Should Attend? \nDrug-delivery developers\, Medical Device Engineers\, Primary Packaging material designers\, Secondary packagers\, Smart device developers\, Training device developers\, Device-safety solution providers\, Drug developers
URL:https://www.pharmajournalist.com/event/smis-pre-filled-syringes-and-injectable-drug-devices/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Group Ltd":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220117
DTEND;VALUE=DATE:20220119
DTSTAMP:20260515T223536
CREATED:20210920T085620Z
LAST-MODIFIED:20211217T131548Z
UID:31698-1642377600-1642550399@www.pharmajournalist.com
SUMMARY:SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
DESCRIPTION:SMi’s 10th Annual Pharmaceutical Microbiology UK Conference  \nConference: 17 – 18 January 2022\nWorkshops: 19 January 2022 \nLocation: Virtual Conference: Online Access Only  \nWebsite: http://www.pharma-microbiology.com/PJwl \nSponsored by: CTL-MAT\, Ecolab and Microgenetics \nChaired by: Di Morris\, Clinical Auditor\, AstraZeneca \nExploring Robust Risk-Based Microbiological Control Strategy \nSMi’s flagship microbiology conference is celebrating its 10 year anniversary. The conference taking place on 17 and 18 January 2021 in London\, UK will bring together microbiology industry experts. \nMicrobiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. The two-day conference will explore the most pressing topics in this thriving field\, from the movement toward process automation and minimisation of operator intervention\, to the latest technologies in rapid microbiological testing methods and data integrity. \n#SMiPharmaMicroUK \nKey Reasons to Attend: \n\nDiscover case studies in establishing holistic Contamination Control Strategies and Real-Time Viable Air Particle Counting with leaders in the pharmaceutical industry\nGain insight the current state of Endotoxin testing\, including alternative test methods and strategic approaches to method validation\nExplore the best practice in data integrity and the automation of environmental monitoring in the Microbiology Quality Control Lab\nJoin the important panel discussion on diversity and inclusion in the workplace with an experienced line-up of speakers\nDiscuss the latest developments in the detailed\, rapid detection of microbes in pharmaceutical water\n\nDownload the brochure at: http://www.pharma-microbiology.com/PJwl \nWho Should Attend? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-10th-annual-pharmaceutical-microbiology-uk-conference/
LOCATION:London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220118
DTEND;VALUE=DATE:20220121
DTSTAMP:20260515T223536
CREATED:20210928T103251Z
LAST-MODIFIED:20210928T103251Z
UID:31764-1642464000-1642723199@www.pharmajournalist.com
SUMMARY:3rd Glioblastoma Drug Development Summit
DESCRIPTION:The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma. \nThrough investigating the clinical implementation of diverse mechanisms of action\, including\, DNA damage repair\, immunotherapy\, oncolytic viruses\, cholesterol metabolism\, PARP inhibitors and more\, we strive to address the urgent need for novel and much improved treatments for this devastating disease. \nTackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic\, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes\, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials. \nWith a huge unmet medical need for effective treatments and too many clinical failures to overcome\, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives. \nJoin us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients. \nTo know more visit: https://ter.li/2bmg9q
URL:https://www.pharmajournalist.com/event/3rd-glioblastoma-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220124
DTEND;VALUE=DATE:20220126
DTSTAMP:20260515T223536
CREATED:20211025T110453Z
LAST-MODIFIED:20211217T125420Z
UID:31919-1642982400-1643155199@www.pharmajournalist.com
SUMMARY:SMi’s Transdermal and Microneedle Delivery
DESCRIPTION:SMi’sTransdermal and Microneedle Delivery\n24-25 January 2022\nWorkshop: 26th January 2022\nVirtual Conference: Online Access Only\nwww.transdermal-microneedle-delivery.co.uk/PharmajournalistWL\n#SMiTransdermal \nSponsored by: LTS Lohmann Therapie-Systeme AG and QuadMedicine \nCo-Chaired by: \nSanjiv Sharma\, Senior Lecturer in Medical Engineering\, Swansea University \nTycho Speaker\, Director\, Drug Delivery and Biomaterials\, AbbVie Ltd \nSMi’s inaugural conference: Transdermal and Microneedle delivery will take place on 24th – 25th January 2022 \nSMi is proud to present the Transdermal and Microneedle Drug Delivery Conference\, taking place on the 24th to 25th January 2022\, Virtual Conference: Online Access Only. Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in the latest innovations in device design and formulation with case studies from thought leaders. \nThe conference will consider key developments in the transdermal drug delivery field\, including the innovations in microneedle technology for a COVID-19 vaccine and opportunities for development in cancer vaccine delivery\, advances in microarray patches\, and microneedle-based diagnostics. Key regulatory updates including guidance on classification of microneedle devices and considerations for ensuring quality will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field\, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts. \nThis two-day agenda offers you peer-to-peer networking with leaders in transdermal and microneedle delivery. We look forward to welcoming you to the conference in January. \nKey Reasons to Attend: \n\nGain insight into developments in microneedles for drug delivery and diagnostics\nHear key regulatory updates from regulatory bodies including FDA and WHO on guidance for regulatory compliance\nExplore new applications of microneedle technology in vaccinations\nDiscover advances in design and application of transdermal patches\nExplore and benchmark against industry developments through case studies and real world examples in device development for microneedles\n\nDownload the brochure at: www.transdermal-microneedle-delivery.co.uk/PharmajournalistWL \nWho Should Attend? \n\nDrug-Delivery  Device Developers\nMicroneedle Device Developers\nTransdermal Delivery  Developers\nMicroarray Patch Developers\nMedical Device Engineers\nPrimary Packaging Material DesignersSecondary Packagers\nSmart Device Developers\nTraining Device Developers\nDevice-Safety Solution Providers\nDrug Developers\nTransdermal Drug Product Developers
URL:https://www.pharmajournalist.com/event/transdermal-and-microneedle-delivery/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Group Ltd":MAILTO:RJones@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223536
CREATED:20211109T085834Z
LAST-MODIFIED:20211109T121023Z
UID:32029-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit Europe
DESCRIPTION:Decipher Mechanisms of Action\, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research \n \nWhilst emerging phase 3 data is set to ignite investment and uncover the reality of microbiome-based therapeutics\, there remain analytical challenges and translational bottlenecks that the community must come together to overcome\, to redefine biopharmaceutical treatment and diagnostic options. \nThe community is now closer than ever to obtaining an available\, approved and commercial microbiome-based therapeutic. This conference joins scientists\, clinicians\, entrepreneurs and academics\, to help assist this success. Persistent hurdles and ongoing challenges with microbiome drug development mean that real-life discussions and learnings are imperative to moving this exciting field forward. \nFrom understanding the microbiome functionality\, leveraging lessons from pre-clinical and clinical development\, scaling manufacturing processes and regulation hurdles\, our discussion will leave you with a holistic view of the European end-to-end development of microbiome therapeutics. \nThe Microbiome Movement provides the perfect opportunity to actualise the therapeutic promise that the microbiome has provided\, by bringing these challenges to the forefront and tackling them head on over three days of extensive content. With the sharing overall aim to commercialise a microbiome-based product. \nTo know more visit: https://ter.li/rk0suq
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit-europe/
LOCATION:The Tower Hotel\, St. Katharine's Way\, London\, E1W 1LD\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223536
CREATED:20211118T125316Z
LAST-MODIFIED:20211118T125437Z
UID:32119-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:HFpEF Drug Discovery & Development Summit 2022
DESCRIPTION:Heart failure affects about 6.2 million people in the United States\, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet\, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and\, like other disease areas\, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes. \nThe HFpEF Drug Discovery & Development Summit 2022 is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities\, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures. \nWith 20+ hours of content\, an interactive workshop\, and over 5 hours of networking with key industry leaders from Amgen\, Cardiobiopharma\, AstraZeneca\, NeoProgen\, Eli Lilly\, Bayer\, Novartis\, and more\, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field. \nMake this your 2022 must-attend meeting and network with 80+ senior CSOs\, CEOs\, research scientists\, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide. \nTake a look at the full event guide here.
URL:https://www.pharmajournalist.com/event/hfpef-drug-discovery-development-summit-2022/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223536
CREATED:20211119T092845Z
LAST-MODIFIED:20211119T094834Z
UID:32188-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:It is clear the world of TGF-β contains vast potential and excitement\, in the past year alone we have seen great advances\, clinical setbacks\, and novel insights into the role of TGF-β. \nOver the last 12 months\, we have seen so many highs and lows\, including clinical updates from large pharma such as Novartis\, Oncotelic Therapeutics\, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate. \nWith the vast volume of candidates moving into the clinic\, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit\, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression. \nTailored with 31+ senior leaders\, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from biology to translational modeling\, from biomarkers to clinical trial design across 3 days. \nWhat’s New? \n\n31+ world-class speakers from Scholar Rock\, Novartis\, Pfizer\, Mestag Therapeutics\, Takeda\, Cue Bio\, Genentech\, and more\n2 Dedicated Tracks of exclusive preclinical and clinical case studies and data for your invaluable lessons learned\nA TGF-β Boot Camp Day to provide a comprehensive guide on harnessing the potential of this complex target\n\nTo know more visit: https://ter.li/nep8yi
URL:https://www.pharmajournalist.com/event/tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223536
CREATED:20211119T093246Z
LAST-MODIFIED:20211119T094530Z
UID:32193-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:DDR\, ATR & PARP Inhibitors Summit
DESCRIPTION:The 5th Annual PARP\, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications. \nThis is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets\, in either monotherapy or in combination\, to treat predictable\, identifiable\, DDR-defective cancer indications. \nIf you are a research team striving to create best-in-class DDR therapeutics\, this is the specific networking forum that has been curated with you in mind. \nWhat Will We Cover? \n\nDelve into the progress in PARP\, ATR & Wee1 including biomarker understanding with AstraZeneca\, Bayer\, Repare\, Merck KGaA\, Atrin Pharma\, IMPACT Therapeutics\, Onxeo\, FoRx & Zentalis\n\n\nOptimize pre-clinical development through models\, novel methodologies & imaging technologies to revolutionize translation with NCI\, XPose Therapeutics\, Dana-Farber Cancer Institute & Harvard\n\n\nUncover the therapeutic potential & progress in targeting Polθ\, WRN\, CHK1\, DNA-PK\, USP1\, PARG\, PKMYT1 with Artios Pharma\, Harvard\, NERx Bio\, KSQ Therapeutics\, IDEAYA & Repare Therapeutics\n\n\nDiscover the clinical updates on combination\, dosing\, scheduling & future directions for this exploding field with Newcastle University\, MD Anderson\, National Brain Tumor Society\, Yale\, Breakpoint Therapeutics & Harvard\n\n\nNetwork In Person with your peers\, ask your burning questions\, build connections\, and fully immerse yourself in the world of DDR therapeutics.\n\n\nA Virtual Attendance Option\, giving you access to the same premium quality content as the in-person event\, dedicated virtual networking opportunities\, & the ability to engage with our event partners\n\nTo know more visit: https://ter.li/uzjvgi
URL:https://www.pharmajournalist.com/event/ddr-atr-parp-inhibitors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223536
CREATED:20211122T104255Z
LAST-MODIFIED:20220104T174404Z
UID:32208-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:mRNA- Based Therapeutics Summit Europe
DESCRIPTION:Built with biopharmaceutical industry insights\, this conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nWith 20+ pioneering large pharma\, biotech and academic experts who are shaping the landscape of mRNA- based therapeutics for the scientific community world-wide\, hear how they address the major challenges facing the industry. \nKey Highlights: \n\nOptimise the Efficacy\, Cell- & Tissue- Specificity & Translatability of Your mRNA- Based Pipeline\n\n With the limitless opportunity of mRNA- based Therapeutics across different modalities\, consider the challenges of efficacy and improve cell- & tissue- specificity with expert insights from Professor Drew Weissman\, Strand Therapeutics & Chalmers University of Technology  \n\nExplore Applications of mRNA- Based Therapeutics Beyond Infectious Diseases\n\n From immune-oncology to rare and autoimmune diseases\, dive into emerging applications and potential challenges of mRNA- based vaccines and therapeutics beyond infectious diseases with case studies from Moderna\, BioNTech & Ethris  \n\nNavigate New & Emerging Delivery Technologies for mRNA- Based Therapeutics\n\n Take yourself to the forefront of mRNA delivery system development\, from structure through to administration with insights from BioNTech\, Johnson & Johnson & 20Med Therapeutics  \n\nStrategise Your Scalable & Global mRNA-Based Vaccine Development \n\n With the global outreach of mRNA- based vaccines\, scalability is a major hurdle. Hear the latest technological advances and regulatory standards in mRNA- based vaccine and therapeutic landscape from Sanofi\, Ziphius Vaccines & Arcturus Therapeutics  \n\nTune into How Companies are Differentiating Their Pipelines Beyond mRNA- Based Vaccines\n\n With the success of mRNA- based vaccines fulfilling novel technologies and therapies such as mRNA- based protein replacement\, hear from companies like Strand Therapeutics\, Turn Biotechnologies & Orna Therapeutics on the emerging strategies that will enable innovation in the field \nTo know more visit: https://ter.li/og1teo
URL:https://www.pharmajournalist.com/event/mrna-based-therapeutics-summit-europe/
LOCATION:Digital Event – CET
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220126
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T223536
CREATED:20211118T130234Z
LAST-MODIFIED:20211118T130317Z
UID:32130-1643155200-1643327999@www.pharmajournalist.com
SUMMARY:5th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:Returning for its fifth year\, the Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges of understanding the mechanisms inducing tolerance\, characterizing driver antigens of disease\, monitoring immune response\, and accelerating durable therapies into the clinic. \nThis is your comprehensive guide to define your drug development strategy for 2022 and delve into the therapeutic opportunity held by the next generation of antigen-specific immunotherapies. Expect to be involved in interactive discussions on: \n\nExamining the mechanisms underlying immune tolerance to drive antigen and epitope discovery with insights from the NIH\, Vaccibody\, and Imcyse\nLeveraging immune biomarkers and explore immune tolerance in diabetes with Novo Nordisk\, COUR Pharmaceuticals\, and Diamyd Medical\nExploring the diversity of technologies and platforms for antigen delivery withToleranzia\, Idogen AB\, and AnTolRx\, Inc\nOptimizing clinical durability and efficacy of antigen-specific immunotherapies with insights from WORG Pharmaceuticals\, and Cellerys\n\nUniting 80+ industry experts to discuss cutting-edge content exploring the latest advances in the field of antigen-specific immune tolerance\, this is a conversation not to miss. \nTake a look at the event guide here.
URL:https://www.pharmajournalist.com/event/5th-antigen-specific-immune-tolerance-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220209
DTEND;VALUE=DATE:20220211
DTSTAMP:20260515T223536
CREATED:20211013T105724Z
LAST-MODIFIED:20220114T094327Z
UID:31828-1644364800-1644537599@www.pharmajournalist.com
SUMMARY:SMi’s 13th Annual RNA Therapeutics Conference
DESCRIPTION:SMi Group’s 13th Annual Conference: \nRNA Therapeutics 2022\n9th – 10th February 2022\nVirtual Conference: Online Access Only\nwww.therapeutics-rna.com \nSponsored by: BIA Separations | eTheRNA Immunotherapies | Thermo Fisher Scientific \nBolstering the latest advances and opportunities in RNA-based medicine \nThe RNA therapeutics industry has grown at an exponential rate in recent years\, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. \nThe 2022 agenda will explore innovations in novel and targeted delivery\, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease\, neurological diseases\, and oncology.
URL:https://www.pharmajournalist.com/event/smis-13th-annual-rna-therapeutics-conference/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Group Ltd":MAILTO:ngaloria@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220209
DTEND;VALUE=DATE:20220211
DTSTAMP:20260515T223536
CREATED:20211210T000811Z
LAST-MODIFIED:20220117T123916Z
UID:32418-1644364800-1644537599@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:SMi’s 5th Annual 3D Cell Culture Conference \nVirtual Conference: Online Access Only \n9-10 February 2022 \nhttp://www.3d-cellculture.com/ \nSponsored by: CELLINK\, CelVivo\, Promega and Newcells BiotechDeveloping Complex\, Translatable and Physiologically-Relevant Cellular Models in vitro \nConference Co-Chairs: Stefan Przyborski\, Professor of Cell Technology\, Durham University and Philip Hewitt\, Global Head of Early Investigative Toxicology\, Merck \n3D Cell Culture is gaining momentum in the pharmaceutical industry on account of the advantages such models pose for in drug discovery\, from improved clinical translation and predictivity\, to patient safety and sustainability. \nSMi’s 3D Cell Culture Conference will explore advances in the application of 3D cell models\, from their employment in drug screening to reduce candidate attrition\, to the latest insights into microphysiological systems\, the regulatory landscape\, and the clinical applications of 3D bioprinting. \nEvent Hashtag: #SMi3DCellCulture \nKey Benefits of Attending: \n\nDiscuss the uses of advanced cell technologies to construct in vitro models of human tissues\nExplore the regulatory sciences surrounding Microphysiological systems\, and their development and adoption for drug safety assessment\nUncover the major benefits of 3D modelling in enhancing clinical translation and predictability\nUtilise 3D cell culture for High Throughput drug discovery and Content screening over traditional 2D methods\n\n\n• Delve into advanced case studies looking into organ models: from organotypic lungs to liver spheroids\n\n WHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference-2022/
LOCATION:Virtual Conference: Online Access Only
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220214
DTEND;VALUE=DATE:20220217
DTSTAMP:20260515T223536
CREATED:20211029T081249Z
LAST-MODIFIED:20211029T081249Z
UID:31932-1644796800-1645055999@www.pharmajournalist.com
SUMMARY:4th Bacteriophage Therapy Summit
DESCRIPTION:From Translation to Market-Entry: Advance Formulation\, Clinical Development\, & Commercialization of Phage-Based Therapies at the 4th Bacteriophage Therapy Summit 2022. \nReturning for its 4th year\, the Bacteriophage Therapy Summit remains the only industry-focused forum dedicated to facilitating the discovery\, translation & acceleration of bacteriophage research into targeted therapeutics with clinically significant results. View the full event guide here: https://ter.li/ehl7e1 \n2022 Agenda Overview: \n\nNavigate clinical trial rationale\, distribution effects of formulation on reaching infection sites\, lessons learned from compassionate use trials\, and the regulatory pathway for commercial development with the hottest insights from our 35+ expert speaker faculty\nHear from international organizations including the FDA\, BiomX\, Locus Bioscience\, Felix Bioscience\, Phagomed\, PhagePro\, Cytophage\, Sciphage and unite with the phage community prioritizing human health and diseas\nDiscuss strategies to weaponize phage therapies including lysins\, genetic engineered and combination approaches to create new pathways for the treatment of infectious diseases\, across 3 days of unparalleled\, industry-centered content\nKeep your company’s interest in bacteriophage therapies up-to-date and aligned with the new breakthroughs beyond basic science and establish your pathway to commercialization in 2022 and beyond\n\nSee our full speaker faculty\, all agenda topics\, and our attending audience in our event brochure: https://ter.li/ehl7e1 \nJoin us to develop the next generation of phage therapy products disrupting the medical and healthcare industries for a better tomorrow. Early booking and group discounts are available upon request. Please visit the website for more information on registration fees and discounts. https://ter.li/1szl1y
URL:https://www.pharmajournalist.com/event/4th-bacteriophage-therapy-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220215
DTEND;VALUE=DATE:20220218
DTSTAMP:20260515T223536
CREATED:20211105T123049Z
LAST-MODIFIED:20211105T123049Z
UID:31997-1644883200-1645142399@www.pharmajournalist.com
SUMMARY:2nd Operationalize: Expanded Access Programs Summit
DESCRIPTION:This 2nd Operationalize: Expanded Access Programs summit is here to bring you solutions. \nBy bringing together the world’s leading Expanded Access Programs thinkers\, this exclusive platform will clarify the complex issues through end-to-end Managed Access/Compassionate Use program operationalization. Through open discussion\, sharing best-practice case studies\, and removing hypotheticals: this event provides an unrivaled opportunity to solve your challenges across the entire timeline. \nWhether it’s program set-up\, US and EU regulatory pathways\, product supply\, data collection\, logistics\, ethical considerations\, or internal collaborating – ensure you aren’t repeating past mistakes by hearing global leaders recall their experiences with a shared goal of providing you with pragmatic solutions to solve these complex hurdles. \nFor more information visit: https://ter.li/f41rv0
URL:https://www.pharmajournalist.com/event/2nd-operationalize-expanded-access-programs-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220221
DTEND;VALUE=DATE:20220224
DTSTAMP:20260515T223536
CREATED:20211202T111335Z
LAST-MODIFIED:20211202T111335Z
UID:32303-1645401600-1645660799@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Europe
DESCRIPTION:LEAP HR: Life Sciences Europe is your best opportunity to uncover the brand-new HR thinking that will enable you to tackle an ongoing talent shortage\, and create the differentiated people strategies and organisational agendas you need to thrive in a hybrid life sciences operating environment. \n \nStep inside 20+ case studies of how biopharma organisations of all sizes are thriving in new-hybrid working models – and leave with the inspiration you need to transform HR impact in your own organisation.  Look beyond what’s previously not been possible and focus on how HR can transform its strategic impact in this fundamentally new working world that will enable your own organisation to compete more effectively for top life sciences talent. \nFind out more > https://ter.li/tw2ss2
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-europe/
LOCATION:The Pestana Amsterdam Riverside\, Amsteldijk 67\, Amsterdam\, 1074 HZ\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T223536
CREATED:20211101T103734Z
LAST-MODIFIED:20211101T103819Z
UID:31980-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
DESCRIPTION:The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit!\nYear on year\, we are proud to unite the leading frontiers of the RAS industry to showcase expertise\, technical data and pipeline updates\, all geared toward accelerating the discovery and development of anti-RAS therapies. \nThis February 2022\, the summit returns to shine a spotlight onto pioneering discoveries and innovative strategies to target RAS\, including a focus on success in targeting mutations beyond G12C and efforts to shut down the RAS/MAPK pathway at every turn. \nAs the industry springboards off the significant success of G12C covalent inhibitors against KRAS mutant cancers\, leading experts are now shifting focus toward next-generation anti-RAS drugs\, considering how we can leverage the RAS signaling pathway to treat all RAS mutant cancers\, and overcome the critical escape mechanisms leading to treatment resistance. \nTo know more visit: https://ter.li/8ljo2k
URL:https://www.pharmajournalist.com/event/3rd-ras-mapk-pathway-targeted-drug-discovery-summit/
LOCATION:8:30am – 5pm | Boston\, MA In-Person and Digital Options Available
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T223536
CREATED:20211109T113013Z
LAST-MODIFIED:20211109T113013Z
UID:32042-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:Next Generation CAR-TCR Summit
DESCRIPTION:As the CAR-T field continues to explode with new companies\, investment\, and clinical collaborations\, it’s more important than ever to stay ahead of the curve. Stakeholders across oncology are now turning to next generation developments and innovations to create the therapies of tomorrow. \nThat’s why CAR-TCR Europe has evolved into the Next Generation CAR-TCR Summit: your definitive platform focused on the 2.0\, next generation innovations in cell therapies. \nJoin you CAR-TCR community and network with 300+ innovators from large pharma\, biotech\, academia and regulatory boards at the only meeting dedicated to accelerating novel\, new generation cell therapies that are safer\, more effective and have meaningful impact in diseases beyond oncology. \nYou’ll hear insights into novel in-vivo delivery\, innovations in gene\, base & prime editing\, novel discovery platforms\, overcoming the hostile tumour microenvironment\, improving persistence & durability for greater clinical outcomes\, and more! \nKey insights will be shared from Matterhorn Biosciences\, Affini-T Therapeutics\, Kiromic BioPharma\, Antion Biosciences\, Zelluna Immunotherapy\, T-Kinfe Therapeutics\, AffyImmune and many more. Leverage their knowledge to deliver value to your entire cell therapy team. \nWith 3 in-depth streams exploring the hottest Novel Platforms\, Advanced Clinical Development of 3rd\, 4th and 5th generation cell therapies\, and the latest Manufacturing Innovations to revolutionise the production of large-scale cell therapy\, this is the ONLY meeting bringing you the next generation developments and innovations needed to create the therapies of tomorrow. \nWhether you are developing novel constructs\, new clinical trial strategies or innovative manufacturing approaches for large scale production\, this multi-tracked meeting can support your whole team and provide the tools needed to advance your own pipeline towards clinical and commercial success. \nView official event guide now for the full meeting details!
URL:https://www.pharmajournalist.com/event/next-generation-car-tcr-summit/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260515T223536
CREATED:20211129T180236Z
LAST-MODIFIED:20211129T180236Z
UID:32287-1645488000-1645747199@www.pharmajournalist.com
SUMMARY:2nd Mitochondria-Targeted Drug Development Summit
DESCRIPTION:We are happy to announce that the Mitochondria-Targeted Drug Development Summit\, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction\, will be delivered in-person\, for its 2nd edition.\nMitobridge/Astellas\, Minovia Therapeutics\, Abliva\, GenSight Biologics\, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies. \nTo know more visit: https://mitochondria-targets.com/
URL:https://www.pharmajournalist.com/event/2nd-mitochondria-targeted-drug-development-summit/
LOCATION:Hyatt Regency Boston / Cambridge\, 575 Memorial Dr\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220301
DTEND;VALUE=DATE:20220304
DTSTAMP:20260515T223536
CREATED:20211118T125811Z
LAST-MODIFIED:20211118T125903Z
UID:32125-1646092800-1646351999@www.pharmajournalist.com
SUMMARY:4th Chronic Kidney Disease Drug Development Summit
DESCRIPTION:As SGLT2 inhibitors redefine standard of care\, opportunities to establish efficacy with surrogate endpoints take a step forward\, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting. \nThe 4th Chronic Kidney Disease Drug Development Summit is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca\, Johnson & Johnson\, Bayer\, Boehringer Ingelheim\, Novartis\, Otsuka\, Novo Nordisk\, and many more\, this is a conversation you cannot afford to miss. \nFrom dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine\, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI\, this is the only end-to-end forum presenting scientific advancements as actionable insights. \nWe hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope\, albuminuria\, and real-world evidence into innovative trial design. \nTake a look at the event guide here.
URL:https://www.pharmajournalist.com/event/4th-chronic-kidney-disease-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220308
DTEND;VALUE=DATE:20220311
DTSTAMP:20260515T223536
CREATED:20211214T011809Z
LAST-MODIFIED:20211214T011809Z
UID:32510-1646697600-1646956799@www.pharmajournalist.com
SUMMARY:Transcription Factor-Directed Therapies Summit
DESCRIPTION:The FDA’s recent approval of Welireg has sparked reinvigorated confidence in the field of Transcription Factor-therapeutics and as an increasing number of drug candidates are entering preclinical and clinical programs\, this is a vital moment for the field. \nFor the first time\, you can join leaders from BMS\, Scorpion Therapeutics\, Ikena Oncology\, Kronos Bio and Talus Bio at the inaugural Transcription Factor-Directed Therapies Summit\, the first in-person conference on precision molecular oncology uniting experts in proteomics\, genomics\, structural biology\, and translational sciences. \nDedicated to overcoming specific drug development challenges of targeting this ubiquitous and highly complex system with novel TPD based modalities\, this unique discussion forum will equip you with the knowledge to utilize Transcription Factors as biomarkers to better predict disease prognosis and progression. \nDon’t miss your chance to join fellow pioneers of Transcription Factor medicine to overcome the critical roadblocks to success in small molecule inhibitors\, PROTAC-based degraders\, and other therapeutic approaches targeting STAT3\, c-MYC\, FOXP3\, p53\, MITF\, NF-B\, and many more Transcription Factors. \nEnsure your Transcription Factor program reaches full clinical potential by gaining a better understanding of the underpinning biology of the transcription regulation network and how it relates to treating disease\, whilst harnessing the novel discovery and screening technologies that are streamlining drug development and opening the field up to new therapeutics possibilities. Join us to seek out solutions to longstanding obstacles in transcription factor therapy development at all stages\, from bench to bedside. \nTo know more visit: https://bit.ly/3pWWEj8
URL:https://www.pharmajournalist.com/event/transcription-factor-directed-therapies-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220314
DTEND;VALUE=DATE:20220316
DTSTAMP:20260515T223536
CREATED:20211220T170251Z
LAST-MODIFIED:20211220T170251Z
UID:32612-1647216000-1647388799@www.pharmajournalist.com
SUMMARY:SMi’s 3rd Annual AI in Drug Discovery Conference
DESCRIPTION:SMi’s 3rd Annual AI in Drug Discovery Conference \nConference: 14 – 15 March 2022\nLondon\, UK\nWebsite: http://www.ai-indrugdiscovery.com/PJwl \nChaired by Darren Green\, Director of Computational Chemistry\, GSK \nSponsored by: Optibrium \nExploring the Impact of Machine Learning and Artificial Intelligence in Drug Development from Discovery to Healthcare \nSMi Group is proud to present its 3rd Annual AI in Drug Discovery Conference\, taking place on the 14th and 15th March 2022 in London\, UK. \nWith the recent pandemic highlighting the need for rapid drug discovery\, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts. \nAI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nAI in drug discovery is becoming an integral part of the research and development area of treating diseases with more companies incorporating ‘Big Data’ and data scientists within their R&D teams. Although the AI in drug discovery area has grown rapidly over the past few years\, those in the industry acknowledge that there is a long way to go. Collaboration and partnerships are the key to driving this area forward. \nJoin us at SMi’s 3rd annual AI in Drug Discovery conference and explore the latest industry updates in: the selection of targets using AI\, decision making within drug discovery and closing the loop on AI in drug discovery. Don’t miss out on presentations from leaders within the field\, giving insights into the latest industry advances and answering the big questions within AI in Drug Discovery. \nEvent Hashtag: #SMiAIDrugDis \nKey Reasons to Attend: \n\nDiscover the main topics of research within industry\, with talks on decision making\, target selection and closing the loop\nEngage with regulators about the guidance within machine learning and AI in Drug Discovery\nLearn about the new breakthroughs within clinical trials and the treatment of disease\nExplore the latest technologies in deep learning from leaders within the pharmaceutical industry\nDiscuss the impact of big data and how it applies to AI drug discovery within Pharma\n\nWho Should Attend? \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-3rd-annual-ai-in-drug-discovery-conference/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR